- Home
- BBNX vs XFOR Comparison
BBNX vs XFOR Comparison
Compare BBNX & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBNX | XFOR |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | 423 | 143 |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.1M | 407.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BBNX | XFOR |
|---|---|---|
| Price | $9.35 | $3.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | ★ $23.80 | $9.00 |
| AVG Volume (30 Days) | ★ 785.3K | 348.1K |
| Earning Date | 04-21-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $34.90 | N/A |
| Revenue Next Year | $34.63 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.80 | $1.35 |
| 52 Week High | $32.71 | $4.83 |
Technical Indicators
Market Signals| Indicator | BBNX | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 38.08 | 35.38 |
| Support Level | $8.80 | $3.57 |
| Resistance Level | $10.97 | $4.09 |
| Average True Range (ATR) | 0.48 | 0.23 |
| MACD | -0.08 | -0.08 |
| Stochastic Oscillator | 17.35 | 6.25 |
Price Performance
Historical ComparisonAbout BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.